Wed, 30 Sep 2020
A conversation between Canadian experts (clinical, pathology and molecular) guided by slide presentation on TRK fusion cancer biology, clinical highlights, testing implementation across Canada and the impact on Canadian patient journeys.
Pathologists, Residents, Medical Students, PAs, Technicians, Medical Oncologists, Molecular Geneticists, Laboratory Directors
At the end of the meeting participants will be able to:
- Understand the biology of TRK fusion cancer
- Review the latest TRK fusion cancer clinical updates and Canadian case studies
- Learn how to implement NTRK gene fusion testing at your institution
- Learn about the FastTRK clinical testing program and success stories presented by testing partners
This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the Canadian Association of Pathologists. You may claim a maximum of 1.0 hour (credits are automatically calculated).
Co-Developed with Bayer & Thermo Fisher
Co-development is defined by the Royal College as the process by which two or more organizations — at least one of which must be a physician organization — prospectively collaborate to develop and implement an accredited educational activity, learning resource or tool.
The physician organization (CAP-ACP) has ultimate authority over all decisions and is accountable to ensure that the administrative, educational and ethical accreditation standards for group learning activities are met.
This webinar was co-developed with Bayer & Thermo Fisher & CAP-ACP and was planned to achieve scientific integrity, objectivity and balance.